Ocular Findings in Alemtuzumab (Campath-1H)-induced Thyroid Eye Disease
| Autor: | Timothy J. Sullivan, Tanya Trinh, Anjana S. Haridas |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Adult medicine.medical_specialty Pathology medicine.medical_treatment Eye disease Thyroid Gland Antineoplastic Agents medicine.disease_cause Antibodies Monoclonal Humanized Autoimmunity Graves' ophthalmopathy 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Alemtuzumab business.industry Multiple sclerosis Thyroid disease Thyroid Thyroidectomy General Medicine medicine.disease eye diseases Graves Ophthalmopathy Ophthalmology medicine.anatomical_structure 030221 ophthalmology & optometry Surgery Female business Tomography X-Ray Computed 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Ophthalmic plastic and reconstructive surgery. 32(6) |
| ISSN: | 1537-2677 |
| Popis: | Alemtuzumab (Campath-1H) is a humanized anti-CD52 monoclonal antibody used in the treatment of multiple sclerosis (MS). Studies demonstrate significant reduction in relapse risk and the risk of accumulating sustained disability. Adverse events include infusion-associated reactions, infections, and secondary autoimmunity. Systemic thyroid disease is the most common secondary autoimmune event and affects up to approximately 30% of treated patients. This is the first description of the ocular findings and management in a case of thyroid eye disease (Graves' Ophthalmopathy [GO]) following alemtuzumab therapy. The ocular disease was managed conservatively while the systemic Graves' was managed with thyroidectomy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|